Anti-TNF agents for rheumatoid arthritis

British Journal of Clinical Pharmacology

Volumn 51, Issue 3, 2001, Pages 201-208

  Seymour, H E ^a   Worsley, A ^a   Smith, J M ^a   Thomas, S H L ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; RHEUMATOID ARTHRITIS; TOXICITY; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DRUG THERAPY; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035029813     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2001.00321.x     Document Type: Article

References (33)

1. Rheumatoid arthritis
2. Adult and juvenile rheumatoid arthritis: Current epidemiological concepts
3. Estimating the incidence of rheumatoid arthritis: Trying to hit a moving target?
4. The economic impact of the rheumatic diseases in the United States
5. The clinical management of rheumatoid arthritis and osteoarthritis: Strategies for improving clinical effectiveness
6. Slow-acting antirheumatic drugs
7. The progression of erosionand joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease
8. Survival and death in rheumatoid arthritis: A 25 year prospective follow up
9. Clinical management of rheumatoid arthritis
10. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis
11. Penicillamine
12. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis
13. Slow drugs: Slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis
14. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial
15. Update in rheumatology
16. Treatment of rheumatoid arthritis with a tumour necrosis factor receptor-fc fusion protein
17. Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor receptor (p75)-Fc fusion protein
18. A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
19. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
20. Etanercept in children with polyarticular juvenile rheumatoid arthritis
21. Anti-TNFα therapy is useful in rheumatoid arthritis and Crohn's disease: Analysis of the mechanism of action predicts utility in other diseases
22. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
23. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis
24. Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
25. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
26. Personal communication. Budgetary implications
27. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in the patients treated with placebo
28. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
29. Stanford health assessment questionnaire modified to assess disability in British patients with rheumatoid arthritis